• About Us
    • Overview
    • Education
    • Mission & History
    • Board of Directors
    • The Campus
    • Careers
  • Our Achievements
    • Overview
    • Cancer
    • Technology
    • Education
    • Our Planet
    • Health & Medicine
    • Physical World
  • Get Involved
    • Overview
    • Partners in Science
    • Estate & Planned Giving
    • Attend an Event
    • Gift Opportunities
  • News & Media
    • Overview
    • News & Media Archive
    • Coronavirus
    • Feature Stories
    • News Releases
    • In The News
    • Video Gallery
    • Ad Campaigns
    • Celebrating Great Minds
  • Blog
  • Contact
  • Donate
Donate
Donate
About Us tri
About Us Overview
  • Education
  • Mission & History
  • Board of Directors
  • The Campus
  • Careers
About Us

Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the benefit of humanity.

Our Achievements tri
Our Achievements Overview
  • Cancer
  • Technology
  • Education
  • Our Planet
  • Health & Medicine
  • Physical World
Our Achievements

The Weizmann Institute’s fundamental research has led to discoveries and applications with a major impact on the scientific community and on the quality of life for millions worldwide.

Get Involved tri
Get Involved Overview
  • Partners in Science
  • Estate & Planned Giving
  • Attend an Event
  • Gift Opportunities
Get Involved

Join a community of dedicated people who share the Weizmann Institute’s commitment to shaping a better world through science.

News & Media tri
News & Media Overview
  • News & Media Archive
  • Coronavirus
  • Feature Stories
  • News Releases
  • In The News
  • Video Gallery
  • Ad Campaigns
  • Celebrating Great Minds
News & Media

Learn about the Weizmann Institute’s latest groundbreaking discoveries and the American Committee’s activities across the country.

Blog tri
  • The Curiosity Review
Blog

Popular science for the curious-minded: The Curiosity Review brings discovery to life.

Contact

Search Results

  • SEARCH BY KEYWORD
  • SEARCH BY TAG
View Articles by Tag:
  • View Articles by Tag
  • Algorithims (6)
  • Alternative energy (27)
  • Alzheimers (44)
  • Archaeology (37)
  • Artificial intelligence (20)
  • Astrophysics (108)
  • Autism (22)
  • Awards (119)
  • Bacteria (107)
  • Behavior (9)
  • Biochemistry (101)
  • Biofuel (7)
  • Biology (309)
  • Biomolecular sciences (7)
  • Blood (43)
  • Brain (175)
  • Cancer (163)
  • Cancer treatment (127)
  • Central nervous system (9)
  • Chemistry (78)
  • Children (7)
  • Circadian clock (1)
  • Climate change (73)
  • Clinical trials (40)
  • Collaborations (19)
  • Community (279)
  • Computers (73)
  • Copaxone (12)
  • Coronavirus (7)
  • Culture (359)
  • Diabetes (32)
  • Earth (74)
  • Education (157)
  • Environment (92)
  • Enzymes (29)
  • Evolution (89)
  • Fertility (20)
  • Fungus (4)
  • Genetics (109)
  • Genomics (3)
  • Heart (5)
  • Heart disease (3)
  • Humanity (83)
  • Immune system (149)
  • Immunology (10)
  • Immunotherapy (34)
  • Inflammation (19)
  • Leadership (114)
  • Leukemia (12)
  • Materials (44)
  • Mathematics (62)
  • Medicine (84)
  • Memory (39)
  • Mental health (58)
  • Metabolism (51)
  • Microbiology (2)
  • Microbiome (10)
  • Molecular cell biology (9)
  • Molecular genetics (61)
  • Multiple sclerosis (12)
  • Nanoscience (33)
  • Nature (4)
  • Neurobiology (2)
  • Neuroscience (207)
  • Nutrition (72)
  • Optics (34)
  • Organs (11)
  • Parkinsons (11)
  • Personalized medicine (5)
  • Philanthropy (148)
  • Physics (139)
  • Plants (56)
  • Proteins (96)
  • Quantum computer (3)
  • Quantum physics (2)
  • Quantum theory (34)
  • Robots (8)
  • Security (21)
  • Senses (115)
  • Sensors (8)
  • Smoking (1)
  • Solar power (19)
  • Space (110)
  • Stem cells (49)
  • Technology (206)
  • Vaccine (40)
  • Virus (135)
  • Water (40)
  • Weather (1)
  • Women (115)
  • World hunger (17)
Filter by Time:
  • All
  • Past Day
  • Past Week
  • Past Month
  • Past Year
  • Past Three Years
Clear Filters

40 results for Clinical trials

Israel's Universal Flu Vaccine Heads for Universal Acceptance
Israel's Universal Flu Vaccine Heads for Universal Acceptance

https://www.weizmann-usa.org/news-media/in-the-news/israel-s-universal-flu-vaccine-heads-for-universal-acceptance/

Oct 29, 2014... Receiving a vaccine (illustrative photo: Miriam Alster/Flash90)
A universal flu vaccine developed by Israel’s BiondVax has been granted patents by both the European Union and Japan, the company announced Wednesday. BiondVax’s technology had previously received patents in the United States, Hong Kong, Australia, China, Russia and Mexico, and the two new approvals extend its reach dramatically.
With the newest patent approvals, the company said that it can now enter into wide-scale development programs with pharmaceutical companies and governments that will license its technology to develop a one-stop-shop vaccine for influenza.

TAGS: Medicine, Humanity, Virus, Clinical trials

Andromeda Biotech Reports that a Drug for Type 1 Diabetes, Developed by Prof. Irun Cohen of the Weizmann Institute, Meets Primary and Secondary Goals of Phase III Clinical Trials
Andromeda Biotech Reports that a Drug for Type 1 Diabetes, Developed by Prof. Irun Cohen of the Weizmann Institute, Meets Primary and Secondary Goals of Phase III Clinical Trials

https://www.weizmann-usa.org/news-media/news-releases/andromeda-biotech-reports-that-a-drug-for-type-1-diabetes-developed-by-prof-irun-cohen-of-the-weizmann-institute-meets-primary-and-secondary-goals-of-phase-iii-clinical-trials/

Nov 22, 2011... REHOVOT, ISRAEL—November 22, 2011—The clinical trial conducted by Andromeda Biotech on a drug developed by Prof. Irun Cohen of the Weizmann Institute of Science to treat Type 1 diabetes was random, regulated, double-blinded, and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel, and South Africa. The involved patients were randomly assigned to one of two groups: one received the trial drug, DiaPep277®, through a subcutaneous injection once every three months, for a period of two years, while the second group, a control group, was given a placebo in the same way. In addition, all of the patients received insulin as needed to stabilize their glucose levels.

TAGS: Medicine, Diabetes, Clinical trials

One Patent, Three Drugs
One Patent, Three Drugs

https://www.weizmann-usa.org/news-media/news-releases/one-patent-three-drugs/

Mar 16, 2016... A protocol that arose from Weizmann Institute of Science research has led to U.S. Food and Drug Administration (FDA) approval of a new biological drug for the treatment of a certain form of lung cancer. This is the third cancer drug to be developed on the basis of studies conducted by the Department of Immunology’s Prof. Michael Sela and colleagues.
Prof. Michael Sela
All three drugs are antibodies that block a receptor called the epidermal growth factor receptor, or EGFR. This receptor, which is on the surface of cells, plays a role in the formation and spread of cancerous tumors. Used in combination with chemotherapy or radiation, blocking EGFR may prevent cancer from growing. Prof. Sela and colleagues Drs. Esther Aboud-Pirak and Esther Hurwitz discovered, a number of years ago, that EGFR-inhibiting antibodies produce a synergistic anticancer effect when used together with chemotherapy.

TAGS: Genetics, Cancer, Cancer treatment, Clinical trials

BiondVax Edges Closer to Elusive Universal Flu Vaccine
BiondVax Edges Closer to Elusive Universal Flu Vaccine

https://www.weizmann-usa.org/news-media/in-the-news/biondvax-edges-closer-to-elusive-universal-flu-vaccine/

Mar 19, 2019... BiondVax CEO Dr. Ron Babecoff (upper row, center) and employees at the company’s new Jerusalem production facility. (photo credit: Courtesy)
New vaccines are developed every year, based on three strains of the influenza virus that experts believe to be most likely in the upcoming season. Frequent and unpredictable mutations of the virus, however, mean that vaccine effectiveness significantly varies from year to year.

TAGS: Immune system, Virus, Proteins, Clinical trials

NeuroQuest to Begin US Clinical Validation Trials for Alzheimer’s Blood Test
NeuroQuest to Begin US Clinical Validation Trials for Alzheimer’s Blood Test

https://www.weizmann-usa.org/news-media/in-the-news/neuroquest-to-begin-us-clinical-validation-trials-for-alzheimer-s-blood-test/

Dec 10, 2015... Prof. Michal Schwartz
CHARLESTON, S.C., Dec. 10, 2015 /PRNewswire/ — NeuroQuest Development Center, Inc., today announced they have entered into a service agreement with the University of California, San Diego for collection and processing of blood samples for their U.S. clinical validation trials.
The South Carolina-based biotech company is developing a blood test for early diagnosis of Alzheimer's disease (AD).

TAGS: Brain, Neuroscience, Immune system, Clinical trials, Alzheimers

Weizmann-Developed Drug May Be Speedy Prostate Cancer Cure, Studies Show
Weizmann-Developed Drug May Be Speedy Prostate Cancer Cure, Studies Show

https://www.weizmann-usa.org/news-media/in-the-news/weizmann-developed-drug-may-be-speedy-prostate-cancer-cure-studies-show/

Apr 03, 2016... Cancer cells (Pixabay)
Scientists at the Weizmann Institute may have found the cure for prostate cancer, at least if it is caught in its early stages – via a drug that doctors inject into cancerous cells and treat with infrared laser illumination.
Using a therapy lasting 90 minutes, the drug, called Tookad Soluble, targets and destroys cancerous prostate cells, studies show, allowing patients to check out of the hospital the same day without the debilitating effects of chemical or radiation therapy or the invasive surgery that is usually used to treat this disease.

TAGS: Technology, Cancer, Cancer treatment, Clinical trials

New Clinical Study Being Launched at the Weizmann Institute of Science
New Clinical Study Being Launched at the Weizmann Institute of Science

https://www.weizmann-usa.org/news-media/news-releases/new-clinical-study-being-launched-at-the-weizmann-institute-of-science/

Apr 08, 2019... REHOVOT, ISRAEL—April 8, 2019—The project, led by Prof. Eran Segal and his team in the Department of Computer Science and Applied Mathematics and Department of Molecular Cell Biology, aims to use state-of-the-art artificial intelligence technologies to generate personalized predictions for disease risk factors. The 10K project is a longitudinal study designed to collect lifestyle and clinical data from 10,000 individuals who will be recruited from the Israeli population, and is suitable for Hebrew speakers only.

TAGS: Molecular genetics, Mathematics, Clinical trials

Could the Flu Become History? An Israeli Vaccine May Make It a Reality
Could the Flu Become History? An Israeli Vaccine May Make It a Reality

https://www.weizmann-usa.org/news-media/in-the-news/could-the-flu-become-history-an-israeli-vaccine-may-make-it-a-reality/

May 06, 2020... A year and a half ago, biochemist Prof. Ruth Arnon, Israel Prize recipient for medicine and past president of the Israel Academy of Sciences and Humanities, received an email from the editor of a science journal. The editor asked whether she planned to attend a conference on multiple sclerosis that was to take place a few days later. Arnon, who was one of the scientists responsible for the research that led to the MS treatment, Copaxone, said she wouldn’t be attending, but was sending a researcher from her lab at the Weizmann Institute of Science.

TAGS: Virus, Vaccine, Proteins, Clinical trials

Israeli Revolutionary Alzheimer’s Treatment to Launch Phase 1 Trial
Israeli Revolutionary Alzheimer’s Treatment to Launch Phase 1 Trial

https://www.weizmann-usa.org/news-media/in-the-news/israeli-revolutionary-alzheimer-s-treatment-to-launch-phase-1-trial/

Sep 10, 2020... A novel treatment for Alzheimer’s, developed by one of Israel’s top scientists, is preparing to launch a Phase 1 clinical trial and, if successful, it could change the course of the disease and arrest its progression.
The therapy, developed by ImmunoBrain Checkpoint and based on 20 years of work by Prof. Michal Schwartz of the Weizmann Institute of Science demonstrating that the immune system is needed for the maintenance of healthy brain function and repair, would contribute to the understanding of the biology of Alzheimer’s disease.

TAGS: Brain, Immune system, Clinical trials, Alzheimers

The Viruses That Fight Disease: A Surprising Precision Weapon against Crohn’s and Ulcerative Colitis
The Viruses That Fight Disease: A Surprising Precision Weapon against Crohn’s and Ulcerative Colitis

https://www.weizmann-usa.org/news-media/news-releases/the-viruses-that-fight-disease-a-surprising-precision-weapon-against-crohn-s-and-ulcerative-colitis/

Aug 04, 2022... REHOVOT, ISRAEL—August 4, 2022—The myriads of microbes in our gut, collectively termed the microbiome, are considered important to our health, but they can also harbor bacteria that contribute to inflammatory bowel disease or other disorders. Currently, however, it is impossible to target such disease-contributing bacteria without harming the surrounding beneficial microbes. Antibiotics kill friendly microbes along with the harmful ones, and in any event, they tend to trigger bacterial resistance and to have side effects. In a study published today in Cell, Weizmann Institute of Science researchers have demonstrated the feasibility of a potential therapy for killing inflammation-causing gut bacteria in a targeted manner: by using viruses that infect them.

TAGS: Medicine, Bacteria, Virus, Inflammation, Clinical trials, Personalized medicine, Microbiome, Immunology

First 1 2 3 4 Last
Back
SHARE

Our Achievements

Learn more about remarkable Weizmann Institute achievements that are enhancing and transforming our lives.

Learn More

Support Our Flagship Projects

Help us accelerate exciting initiatives in three forward-looking fields: neuroscience, physics, and artificial intelligence.

Learn More

Newsletter

Get the latest news and breakthroughs from the Weizmann Institute of Science.

About Us
  • Education
  • Mission & History
  • Board of Directors
  • The Campus
  • Careers
Our Achievements
  • Cancer
  • Technology
  • Education
  • Our Planet
  • Health & Medicine
  • Physical World
Get Involved
  • Partners in Science
  • Estate & Planned Giving
  • Attend an Event
  • Gift Opportunities
News & Media Blog: Curiosity Review Donate Now Contact Us
Privacy Policy Gift Acceptance Policy Financial Information

©2023 American Committee for the Weizmann Institute of Science

Charity Navigator

FOR THE FOURTH CONSECUTIVE YEAR

Platinum Transparency 2023